Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2020-11-30 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
股东股份减持的进展公告
Major Shareholding Notification Classification · 100% confidence The document is a shareholder announcement regarding the progress of a shareholding reduction by a specific shareholder, Zhejiang Beicheng Investment Management Partnership. It details the number of shares reduced, the methods of reduction, dates, prices, and the shareholder's holdings before and after the reduction. It references compliance with relevant regulations on shareholder and insider share reductions. The document is not a financial report, earnings release, or management discussion, but a formal notification about changes in significant share ownership levels. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming this classification.
2020-11-30 Chinese
股东股份减持的进展公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the progress of a shareholder's share reduction (shareholding decrease) in the company. It details the number of shares reduced, the methods of reduction, the period, prices, and the shareholder's holdings before and after the reduction. It references compliance with relevant regulations on shareholder share reduction. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a shareholder's transaction in their own shares, which fits the definition of 'Transaction in Own Shares' (POS). The document length is short (1430 characters), and it contains detailed information about the share reduction, not just a notice or link to a report, so it is not a report publication announcement or regulatory filing. Therefore, the correct classification is POS with high confidence.
2020-11-27 Chinese
关于盐酸恩沙替尼获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from 贝达药业股份有限公司 regarding the receipt of a drug registration certificate for 盐酸恩沙替尼胶囊 (贝美纳). It details the drug's approval, clinical research, market status, and risk warnings. The document is relatively short (2054 characters) and serves as a formal notification to investors and the public about regulatory approval and related information. It does not contain financial statements, earnings data, or detailed management discussion. It is not a full annual or interim report, nor a call transcript or governance document. The content fits the category of a regulatory announcement about a significant company event (drug approval). Therefore, the best classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-11-19 Chinese
关于盐酸恩沙替尼药品注册进展的提示性公告
Regulatory Filings Classification · 100% confidence The document is a short announcement from a company about the progress of a drug registration application with the National Medical Products Administration (国家药监局). It states the status update of the application and promises to disclose further details once official documents are obtained. The document is only 425 characters long and does not contain any financial data, financial results, or detailed report content. It is clearly an announcement of a regulatory or procedural update rather than a full report or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-19 Chinese
股东股份减持的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a shareholder's reduction in shareholding. It details the number of shares reduced, the methods of reduction, the time period, and compliance with relevant regulations. It does not contain financial statements or performance data, nor is it a report or presentation. It is a notification about a shareholder's transaction in their own shares, specifically a reduction in holdings by a director or significant shareholder. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on this transaction, confirming it is not a full report or other type of filing.
2020-11-16 Chinese
关于诉讼案件进展的公告
Legal Proceedings Report Classification · 100% confidence The document is an announcement regarding the progress of a litigation case involving the company. It details the basic situation of the lawsuit, recent developments including court decisions and notifications, and the potential impact on the company's profits. There are no financial statements or detailed financial data presented. The document is primarily a legal proceedings update and does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a certification or a report publication announcement. Therefore, the most appropriate classification is Legal Proceedings Report (LTR).
2020-11-16 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.